Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Research output: Contribution to journalReviewResearchpeer-review

  4. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fatal kakeksi ved mitokondriel neurogastrointestinal encefalomyopati.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Autoimmun autonom ganglionopati hos en patient med nydiagnosticeret type 1-diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Treatment with intravenous immunoglobulin (IVIG) leads to transient side effects such as headache and nausea during and after the infusion. We hypothesized that subcutaneous administration of smaller doses of immunoglobulin (SCIG) given more frequently leads to less severe headache and nausea and could be an alternative in patients experiencing side effects. Fifty-nine patients diagnosed with neurological disorders (chronic inflammatory demyelinating polyneuropathy (CIDP), multi-focal motor neuropathy (MMN) or post-polio syndrome) were treated with IVIG, and 27 CIDP or MMN patients with SCIG. For two consecutive weeks daily, registration of the severity of headache and nausea was registered on a visual analogue scale (VAS) from 0 to 100 mm. In the SCIG group, headache reached a peak value of 1 (0-13) mm at day 6 versus 11 (0-96) mm in the IVIG group at day 4 (p < 0.0001). For nausea, the SCIG group had a stable value of 0 (0-21) mm at all days, whereas a peak value of 3 (0-90) mm was reached at day 4 in the IVIG group (p < 0.0001). SCIG leads to less severe headache and nausea than IVIG without fluctuations of side effects in relation to the injections.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Volume117
Issue number6
Pages (from-to)409-12
Number of pages4
ISSN1742-7843
DOIs
Publication statusPublished - Dec 2015

ID: 46040035